Adam R, Castaing D, Azoulay D, Majno P, Samuel D, Bismuth H
Centre Hépato-Biliaire, Hôpital Paul-Brousse, Yillejuif.
Ann Chir. 1998;52(6):547-57.
Liver transplantation is a treatment for hepatocellular carcinoma in cirrhosis which is both recognized, because potentially radical, and controversial because associated with a high risk of recurrence. This study reports the results of a consecutive series of 125 patients transplanted for hepatocellular carcinoma in cirrhosis over an 11-year period. Liver transplantation was indicated because of the tumour in 92 cases (74%) and the tumour was an incidental finding in 13 cases (10%) or was discovered on histological examination of the hepatectomy specimen in 20 cases (16%). The operative mortality at two months was 4% with a 20% morbidity, due to vascular (6%) or biliary (14%) complications. Tumour recurrence was observed in 26 patients (21%) Recurrence was exceptional in the incidental or histological forms of hepatocellular carcinoma (5%) and more frequent when the tumour constituted the indication for transplantation (27%). The risk of recurrence and the survival were significantly influenced by the maximal tumour diameter (greater than 30 mm), the number of tumour nodules (greater than 3) and the presence of portal invasion. Inclusion of these factors in patient selection during the second phase of the study allowed a reduction of the risk of recurrence from 33 to 11% and improvement of the 3-year post-transplantation survival from 53 to 76%. Tumours less than or equal to 30 mm in diameter, with no more than 3 nodules, and without portal invasion are ideal indications for transplantation. Tumours with more than 3 nodules and larger than 30 mm appear to constitute a contraindication to transplantation, unless tumour reduction can be achieved by chemoembolization. Intermediate forms of hepatocellular carcinoma between these two extreme forms are possible indications for transplantation, depending on the availability of liver transplants.
肝移植是治疗肝硬化肝细胞癌的一种方法,它既有被认可的一面,因为可能具有根治性,又存在争议,因为与高复发风险相关。本研究报告了在11年期间连续125例因肝硬化肝细胞癌接受移植患者的结果。92例(74%)患者因肿瘤而接受肝移植,13例(10%)患者肿瘤为偶然发现,20例(16%)患者肿瘤是在肝切除标本的组织学检查中发现的。两个月时的手术死亡率为4%,发病率为20%,原因是血管(6%)或胆道(14%)并发症。26例(21%)患者出现肿瘤复发。在偶然发现或组织学形式的肝细胞癌中复发情况罕见(5%),而当肿瘤是移植指征时复发更常见(27%)。复发风险和生存率受到肿瘤最大直径(大于30mm)、肿瘤结节数量(大于3个)和门静脉侵犯情况的显著影响。在研究的第二阶段,将这些因素纳入患者选择标准后,复发风险从33%降至11%,移植后3年生存率从53%提高到76%。直径小于或等于30mm、结节不超过3个且无门静脉侵犯的肿瘤是理想的移植指征。结节超过3个且直径大于30mm的肿瘤似乎构成移植禁忌,除非能通过化疗栓塞实现肿瘤缩小。这两种极端形式之间的中间型肝细胞癌可能是移植指征,具体取决于肝移植的可获得性。